Real-world incidence of venetoclax toxicities in British Columbia.
Cassandra LeeAdeline MarkarianFatima LadhaLynne NakashimaMario de LemosKimberly SchaffStephanie WooAlina GerriePublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
The incidence of TLS in patients treated with venetoclax for r/r CLL in BC was lower than in other real-world studies. Findings may warrant further investigation to determine if the higher incidence of TLS in real-world reports may be mitigated through modifying TLS risk categorization and associated prophylactic measures. Neutropenia was the most common grade 3 or 4 venetoclax toxicity reported, and the incidence in BC is comparable to other centres.